Citations

Showing 10 of 108119 citations.

Association of Essential Tremor With Novel Risk Loci
Liao, Calwing , Castonguay, C, Heilbron, Karl , Vuokila, Veikko , Medeiros, Miranda , Houle, Gabrielle, Ross, Jay P. , Catoire, Hélène, Mueller, Stefanie H., Girard, Simon L., Hopfner, Franziska , Lorenz, Delia, Clark, Lorraine N. , Soto-Beasley, Alexandra I., Klebe, Stephan, Hallett, M, Wszolek, Zbigniew K., Pendziwiat, Manuela , Lorenzo‐Betancor, Oswaldo , Seppi, Klaus, Berg, Daniela, Vilariño-Güell, Carles, Postuma, Ronald B., Dupré, Nicolas, Jankovic, J, Testa, C M, Ross, o, Arzberger, Thomas, Chouinard, Sylvain, Louis, Elan D., Mandich, Paola , Cc, Vitale, Barone, Paolo, García-Martín, Elena, Alonso-Navarro, Hortensia, Agúndez, José A. G. , Fj, Jiménez-Jiménez, Pástor, Pau , Rajput, Alex, Deuschl, Günther, Kuhlenbaümer, Gregor, Meijer, Inge A., Dion, Patrick A., Rouleau, Guy A., Ross, Owen A. , Berg, Daniela , Vilariño‐Güell, Carles , Dupré, Nicolas , Soto‐Beasley, Alexandra I. , Agúndez, José A G , Ross, Owen A , Pastor, Pau , Beasley, Alexandra I , Hopfner, Franziska , Castonguay, Charles-Etienne , Akçimen, Fulya , Díez-Fairén, Mónica , Kang, Jooeun , Girard, Simon , Klebe, Stephan , Wszołek, Zbigniew K. , Seppi, Klaus , Berg, Daniela, Postuma, Ronald B. , Bernard, Geneviève , Jankovic, Joseph J. , Testa, Claudia M. , Arzberger, Thomas, Louis, Elan D. , Vitale, Carmine , Barone, Paolo , García‐Martín, Elena , Alonso‐Navarro, Hortensia , Jiménez-Jiménez, F J , Rajput, Alex, Deuschl, Günther , Kuhlenbäumer, Gregor , Dion, Patrick A. , Rouleau, Guy Armand

Mayo Clinic

JAMA Neurology | January 4, 2022 | Volume: 79 | Issue: 2 | Pages: 185

10.1001/jamaneurol.2021.4781 | PMID 34982113 Get It

Editorial for “Elaboration of Multiparametric MRI‐Based Radiomics Signature for the Preoperative Quantitative Identification of the Histological Grade in Patients With Non‐Small‐Cell Lung Cancer”
Li, Zhiqiang , Zhou, Yuxiang , Srivastava, Shiv P., Zhou, Yuxiang

Mayo Clinic

Journal of Magnetic Resonance Imaging | January 4, 2022 | Volume: 56 | Issue: 2 | Pages: 590-591

10.1002/jmri.28052 | PMID 34981578 Get It

Abstract P072: Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) foster myeloid-derived suppressor cell-mediated tumor immune evasion in cholangiocarcinoma
Loeuillard, Emilien , Yang, Jingchun , Wang, Juan , Dong, Haidong , Gores, Gregory J. , Ilyas, Sumera I.

Mayo Clinic

Cancer Immunology Research | January 4, 2022 | Volume: 10 | Issue: 1_Supplement | Pages: P072-P072

10.1158/2326-6074.tumimm21-p072 Get It

Abstract Background and Aims: Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is predominantly expressed on immune cells. Although TRAIL biology has garnered considerable interest as a potential anti-cancer strategy, TRAIL agonists have had very limited anti-cancer activity in humans. TRAIL signaling in T cells may also potentially provide an immune checkpoint function as it can inhibit T cell activation and proliferation by interfering with T cell receptor signaling. However, this potential immune checkpoint function of TRAIL has not been examined in cancer biology. Cholangiocarcinoma (CCA), a highly lethal biliary tract cancer, provides a model to examine the potential immune checkpoint function of TRAIL. Methods: Using a syngeneic, orthotopic murine model of CCA (PMID: 29464042), murine CCA cells (SB cells) that express both TRAIL and TRAIL receptor (TR) were implanted into livers of WT and Tr−/− mice. Hence, in this model the host immune cells express TRAIL but not the receptor; therefore, they would be capable of inducing TRAIL-mediated apoptosis in CCA cells but would be resistant to TRAIL-mediated immunosuppression. After 4 weeks of tumor growth, mice were sacrificed, and tumors were characterized using flow cytometry. Results: We observed that Tr−/− mice had a significant reduction in tumor burden compared to WT mice. Moreover, tumor bearing Tr−/− mice had a significant increase in cytotoxic T lymphocytes (CTLs) and enhanced CTL effector function. However, coculture of T cells with SB cells or SB cells deficient in Tr (SB-Tr−/−) did not result in a significant difference in T cell apoptosis or function, implying that TRAIL-TR is not a direct T cell checkpoint. Myeloid derived suppressor cells (MDSCs) were significantly decreased in Tr−/− tumors compared to WT tumors. Furthermore, implantation of SB cells devoid of Trail (SB-Trail−/−) into WT mice resulted in a significant reduction in tumor burden and MDSC infiltration. Coculture of SB cells with MDSCs from Tr−/− mice attenuated MDSC proliferation and immunosuppression compared to WT MDSCs. Moreover, treatment of MDSCs from Tr−/− mice with TRAIL recombinant protein resulted in a reduction in their proliferation and immunosuppressive function compare to MDSCs from WT mice implying that TRAIL-TR fosters MDSC growth and immunosuppressive function. In conclusion, we have demonstrated that Tr−/− mice have a significant reduction in CCA tumor burden and MDSC infiltration. Consequently, Tr−/− mice bearing tumors have enhanced CTL infiltration and function. These data suggest that the TRAIL-TR system mediates tumor immune evasion via MDSCs. Herein, we suggest that TRAIL-TR appears to function as an indirect T cell checkpoint by augmenting the immunosuppressive effects of MDSCs. Citation Format: Emilien Loeuillard, Juan Wang, Jingchun Yang, Haidong Dong, Gregory Gores, Sumera Ilyas. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) foster myeloid-derived suppressor cell-mediated tumor immune evasion in cholangiocarcinoma [abstract]. In: Abstracts: AACR Virtual Special Conference: Tumor Immunology and Immunotherapy; 2021 Oct 5-6. Philadelphia (PA): AACR; Cancer Immunol Res 2022;10(1 Suppl):Abstract nr P072.
Clinical characteristics and outcomes of ocular adnexal mantle cell lymphoma
Becerra, Clara M. Castillejo , Jevremović, Dragan , Hodge, David O. , Tooley, Andrea A. , Castillejo Becerra, Clara M, Jevremovic, Dragan , Tooley, Andrea A , Castillejo Becerra, Clara M , Dalvin, Lauren A.

Mayo Clinic

Orbit | January 4, 2022 | Volume: 41 | Issue: 1 | Pages: 97-104

10.1080/01676830.2021.2018715 | PMID 35100932 Get It

Outcomes of patients with thromboembolic events following coronavirus disease 2019 AstraZeneca vaccination: a systematic review and meta-analysis
Than, Christian A. , Nakanishi, Hayato , Daniel, Rohan Suresh , Smayra, Karen , Sim, Bernice L. , Danoun, Omar A. , Matar, Reem H, Than, Christian A , Matar, Reem , Beran, Azizullah

Mayo Clinic

Blood Coagulation & Fibrinolysis | January 4, 2022 | Volume: 33 | Issue: 2 | Pages: 90-112

10.1097/mbc.0000000000001113 | PMID 34980833 Get It

AstraZeneca coronavirus disease 2019 (COVID-19) vaccinations have recently been implicated in thromboembolism formations. Our aim was to investigate the outcomes of patients with thromboembolic events following the AstraZeneca vaccine (ChAdOx1 nCoV-19, AZD1222). A literature search was performed from December 2019 to September 2021. Eligible studies must report participants older than 18 years vaccinated with AstraZeneca and outcomes of thromboembolic events. Pooled mean or proportion were analyzed using a random-effects model. A total of 45 unique studies (number of patients = 144, 64.6% women, mean age 21–68 years) were included. The most common presenting adverse events were headache (12.1%), intracerebral hemorrhage (7.5%), and hemiparesis (7%). The most common thromboembolic adverse events were cerebral venous sinus thrombosis (38.5%) and deep vein thrombosis/pulmonary embolism (21.1%). The most common radiologic finding were intracerebral hemorrhage and cerebral venous thrombosis. Laboratory findings included thrombocytopenia (75%) and hypofibrinogenemia (41%). On admission, 64 patients tested positive for PF4-Heparin ELISA assay (80%). Seventy-four patients were hospitalized with 22 being admitted to the ICU. A total of 78 patients recovered while 39 patients died. This meta-analysis presents evidence to suggest vaccine-induced immune thrombotic thrombocytopenia (VITT) following AstraZeneca vaccine. Clinical practice must, therefore, account for the possibility of VITT and subsequent embolic events in certain individuals’ postvaccination with adenovirus-based COVID-19 vaccines. Serum anti-PF4 suggests diagnostic value for VITT and could subsequently inform treatment choices in such instances.
Complex Patellofemoral Reconstruction for Recurrent Instability
Floyd, Edward R. , Kennedy, Nicholas I. , Tagliero, Adam J. , Carlson, Gregory B. , Tagliero, Adam , Floyd, Edward R. , LaPrade, Robert F.

Mayo Clinic

Video Journal of Sports Medicine | January 4, 2022 | Volume: 2 | Issue: 1 | Pages: No page available

10.1177/26350254211035396 | PMID 40309563 Get It

Background: Patellofemoral instability is due to a combination of bony and soft tissue factors. While recurrent patellar dislocations are rare, evaluation and treatment of these conditions require addressing patellar height and lateralization of the tibial tubercle (TT), restraint to lateral patellar subluxation, and trochlear dysplasia. Other factors to consider are coronal limb-length alignment outside of the physiologic 5 to 8° of valgus, which may significantly alter the Q angle and contribute to lateral instability. Other ligaments around the patella contribute to soft-tissue restraint, including the medial and lateral patellotibial ligaments, patellomeniscal ligaments, and the medial quadriceps tendon femoral ligament. Patellar tilt is assessed with and without quadriceps contraction to further evaluate the patella’s relationship to the trochlear groove. The Caton-Deschamps Index, as well as patellar trochlear index (PTI), are used to measure patellar height for patella alta or baja. Technique Description: The technique is to surgically manage a patient in neutral mechanical alignment on standing limb radiographs, with moderate-to-severe DeJour type B trochlear dysplasia and a trochlear sulcus angle of around 145°, patella alta with a Caton-Deschamps Index of 1.6 and PTI of 0.22, a TT to trochlear groove (TT-TG) distance of 8 mm, and a deficient medial patellofemoral ligament (MPFL). The MPFL reconstruction is done first, with harvesting of the ipsilateral quadriceps tendon and maintenance of its distal attachment on the superior patellar pole. The quadriceps tendon graft is folded medially upon its distal attachment and fixed in this position with suture anchors. Tibial tubercle osteotomy is accomplished by spacing drill holes 2 mm apart, medially and laterally, on the TT and connecting the drill holes with an osteotome and reciprocating saw. A distalized location to secure the TT is selected and superficial bone is excised. A medial parapatellar arthrotomy is performed, and bur attachments are used to drill into the subchondral bone beneath the femoral articular surface to create a V-shaped flap of trochlear cartilage. An arthroscope is inserted under the trochlear flap during this process to visualize the appropriate depth. The trochlear flap is then secured with screws passed over guide pins to secure the flap to the desired location. Cannulated screws and washers are then used to secure the TT to its distalized and/or medialized position, with fluoroscopic verification of screw depth and location. The arthrotomy is then closed with the knee at 45°. The quadriceps graft is passed through a subretinacular channel and secured with suture anchors, adjacent to the adductor tubercle, to complete the MPFL reconstruction. Before closure, appropriate tracking and translation of the patella is verified. Results: Sulcus-deepening trochleoplasty, with or without MPFL reconstruction, has been reported to obtain satisfactory outcomes at 2 years, with close to 85% return to sport and 100% return to work, with improvements in International Knee Documentation Committee (IKDC) scores from 50.8 to 79.1 in some studies. MPFL reconstruction with tibial tubercle osteotomy (TTO) has yielded a 94.5% patient satisfaction rate in the literature. Discussion/Conclusion: In patients with recurrent patellar instability and DeJour types B-D trochlear dysplasia, MPFL reconstruction with TTO and sulcus-deepening trochleoplasty provides excellent subjective outcomes and restores patellar tracking with elimination of recurrent subluxation.
Gilteritinib clinical activity in relapsed/refractory FLT3 mutated acute myeloid leukemia previously treated with FLT3 inhibitors
Rahman, Zaid Abdel , Grenet, Justin , Boisclair, Stéphanie , Bewersdorf, Jan Philipp , Barth, Dylan , Fraga, Martina , Bixby, Dale L. , Zeidan, Amer M. , Desai, Pankil , Mannis, Gabriel N. , Deutsch, Yehuda E., Dinner, Shira, Frankfurt, Olga, Litzow, Mark R. , Al‐Kali, Aref , Foran, James M. , Sproat, Lisa Z., Jovanovic, Borko, Perl, Alexander E. , Altman, Jessica K. , Rahman, Zaid H. Abdel , Numan, Yazan , Abdel Rahman, Zaid, Bewersdorf, Jan P , Yilmaz, Musa , Litzow, Mark R. , Daver, Naval , Altman, Jessica K , Abdel Rahman, Zaid H , Zeidan, Amer M , Collins, Cailin T. , Yılmaz, Musa , Abaza, Yasmin , Daver, Naval

Mayo Clinic

American Journal of Hematology | January 4, 2022 | Volume: 97 | Issue: 3 | Pages: 322-328

10.1002/ajh.26447 | PMID 34981560 Get It

AbstractGilteritinib is approved for the treatment of relapsed/refractory (R/R) acute myeloid leukemia (AML) with an FLT3‐mutation (FLT3mut+). However, the gilteritinib phase 3 ADMIRAL study (Perl et al NEJM 2019) was conducted prior to widespread adoption of either midostaurin as a component of standard intensive induction and consolidation or posttransplant FLT3 inhibitor maintenance. We performed a retrospective analysis using data from 11 US centers and where we identified 113 patients who received gilteritinib alone or as combination therapy for the treatment of R/R FLT3mut+ AML. The composite complete remission (CR) rate (CRc, defined as CR + CRi + CR with incomplete platelet recovery [CRp]) was 48.7% (n = 55). The CRc rate after treatment with gilteritinib in patients who were treated with only prior 7+3 and midostaurin with or without consolidation was 58% with a median survival of 7.8 months. Survival was longest in patients who obtained a CR, particularly a cMRD (clinical minimal or measurable residual disease) negative response; this remained significant after censoring at the time of stem cell transplant. The mitogen‐activated protein kinase pathway activating mutations that are known for gilteritinib resistance (NRAS, KRAS, and PTPN11) had lower CRc (35% vs. 60.5%) and lower median overall survival than patients' whose leukemia did not express these mutations (4.9 months vs. 7.8 months) (HR 2.4; 95% CI 1. 5.4) p value <.01.
Diagnosis and monitoring of systemic sclerosis-associated interstitial lung disease using high-resolution computed tomography
Khanna, Dinesh , Brown, Kevin M. , Chung, Lorinda, Matteson, Eric L. , Kazerooni, Ella A. , Walsh, Simon LF, Maher, Toby M. , Chung, Leland W.K. , Chung, Lorinda , Maher, Toby , Khanna, Dinesh , Distler, Oliver , Cottin, Vincent , Chung, Lorinda, Goldin, Jonathan , McNitt‐Gray, Michael F.

Mayo Clinic

Journal of Scleroderma and Related Disorders | January 4, 2022 | Volume: 7 | Issue: 3 | Pages: 168-178

10.1177/23971983211064463 | PMID 36211204 Get It

Patients with systemic sclerosis are at high risk of developing systemic sclerosis–associated interstitial lung disease. Symptoms and outcomes of systemic sclerosis–associated interstitial lung disease range from subclinical lung involvement to respiratory failure and death. Early and accurate diagnosis of systemic sclerosis–associated interstitial lung disease is therefore important to enable appropriate intervention. The most sensitive and specific way to diagnose systemic sclerosis–associated interstitial lung disease is by high-resolution computed tomography, and experts recommend that high-resolution computed tomography should be performed in all patients with systemic sclerosis at the time of initial diagnosis. In addition to being an important screening and diagnostic tool, high-resolution computed tomography can be used to evaluate disease extent in systemic sclerosis–associated interstitial lung disease and may be helpful in assessing prognosis in some patients. Currently, there is no consensus with regards to frequency and scanning intervals in patients at risk of interstitial lung disease development and/or progression. However, expert guidance does suggest that frequency of screening using high-resolution computed tomography should be guided by risk of developing interstitial lung disease. Most experienced clinicians would not repeat high-resolution computed tomography more than once a year or every other year for the first few years unless symptoms arose. Several computed tomography techniques have been developed in recent years that are suitable for regular monitoring, including low-radiation protocols, which, together with other technologies, such as lung ultrasound and magnetic resonance imaging, may further assist in the evaluation and monitoring of patients with systemic sclerosis–associated interstitial lung disease. A video abstract to accompany this article is available at: https://www.globalmedcomms.com/respiratory/Khanna/HRCTinSScILD
New Therapy for Spinal Cord Injury: Autologous Genetically-Enriched Leucoconcentrate Integrated with Epidural Electrical Stimulation
Исламов, Р. Р. , Bashirov, F. V , Izmailov, Andrei , Fadeev, Filip , Markosyan, Vage , Sokolov, Mikhail , Шмаров, М. М. , Lavrov, Igor , Islamov, Rustem , Shmarov, Maksim , Lavrov, Igor , Logunov, Denis Y. , Naroditsky, Boris S.

Mayo Clinic

Cells | January 3, 2022 | Volume: 11 | Issue: 1 | Pages: 144

10.3390/cells11010144 | PMID 35011706 Get It

The contemporary strategy for spinal cord injury (SCI) therapy aims to combine multiple approaches to control pathogenic mechanisms of neurodegeneration and stimulate neuroregeneration. In this study, a novel regenerative approach using an autologous leucoconcentrate enriched with transgenes encoding vascular endothelial growth factor (VEGF), glial cell line-derived neurotrophic factor (GDNF), and neural cell adhesion molecule (NCAM) combined with supra- and sub-lesional epidural electrical stimulation (EES) was tested on mini-pigs similar in morpho-physiological scale to humans. The complex analysis of the spinal cord recovery after a moderate contusion injury in treated mini-pigs compared to control animals revealed: better performance in behavioural and joint kinematics, restoration of electromyography characteristics, and improvement in selected immunohistology features related to cell survivability, synaptic protein expression, and glial reorganization above and below the injury. These results for the first time demonstrate the positive effect of intravenous infusion of autologous genetically-enriched leucoconcentrate producing recombinant molecules stimulating neuroregeneration combined with neuromodulation by translesional multisite EES on the restoration of the post-traumatic spinal cord in mini-pigs and suggest the high translational potential of this novel regenerative therapy for SCI patients.